Our findings elucidate the regulatory effects of the gut microbiome on the immune microenvironment after RT for HCC and suggest that a healthy gut microbiome may have clinical value as an extracellular agonist of STING, which plays essential roles in gut microbiome-mediated antitumor immune modulation. Here, STING1 is linked to hepatocellular carcinoma.